Cargando…

Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piazza, Gregory, Spyropoulos, Alex C., Hsia, Judith, Goldin, Mark, Towner, William J., Go, Alan S., Bull, Todd M., Weng, Stephen, Lipardi, Concetta, Barnathan, Elliot S., Bonaca, Marc P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270282/ https://www.ncbi.nlm.nih.gov/pubmed/37154020 http://dx.doi.org/10.1161/CIRCULATIONAHA.123.063901

Ejemplares similares

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2019)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease
por: Volkl, Albert A., et al.
Publicado: (2023)

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
por: Dragoni, Francesco, et al.
Publicado: (2018)

IMPACT OF THROMBOPROPHYLACTIC STRATEGY ON BLEEDING RISK AMONG IN- AND OUTPATIENTS WITH COVID-19
por: Svet, Mark, et al.
Publicado: (2021)

Hospital-based use of thromboprophylaxis in patients with COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2020)

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients
por: Raskob, Gary E., et al.
Publicado: (2021)

Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
por: Hess, Connie N., et al.
Publicado: (2022)

Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors
por: Spyropoulos, Alex C., et al.
Publicado: (2021)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Studying the coagulopathy of COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2022)

Low-dose rivaroxaban: can cardiovascular events be reduced?
por: De Luca, Leonardo
Publicado: (2023)

Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization
por: Chaudhury, Pulkit, et al.
Publicado: (2022)

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
por: Cohen, H, et al.
Publicado: (2015)

Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
por: Peacock, W. Frank, et al.
Publicado: (2022)

Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
por: Agarwal, Ajay, et al.
Publicado: (2013)

Thrombotic Events Associated to Aspirin Therapy
por: Doutremepuich, Christian, et al.
Publicado: (2012)

Thrombotic events and COVID-19 vaccines
por: Brazete, C., et al.
Publicado: (2021)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Risk of thrombotic events after respiratory infection requiring hospitalization
por: Smilowitz, Nathaniel R., et al.
Publicado: (2021)

Preadmission Oral Anticoagulation for Atrial Fibrillation/Flutter and Death or Thrombotic Events During COVID-19 Admission
por: Louis, David W., et al.
Publicado: (2022)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Management and Outcome in 32 Neonates with Thrombotic Events
por: van Elteren, H. A., et al.
Publicado: (2011)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor–Treated Patients: Reconciling Adjudicated and Coded Outcomes
por: Kondapalli, Lavanya, et al.
Publicado: (2022)

Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya
por: Njuguna, Dennis, et al.
Publicado: (2023)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain
por: Granero Xiberta, Xavier, et al.
Publicado: (2016)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series
por: Šimičević, Livija, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_20j0idscfsc6i1t6d3li7hh3n8